1. Market Research
  2. > Pharmaceutical Market Trends
  3. > NovaBay Pharmaceuticals, Inc. - Product Pipeline Review - 2014

NovaBay Pharmaceuticals, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 28 pages

NovaBay Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘NovaBay Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the NovaBay Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NovaBay Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NovaBay Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NovaBay Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the NovaBay Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate NovaBay Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NovaBay Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NovaBay Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NovaBay Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NovaBay Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NovaBay Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

NovaBay Pharmaceuticals, Inc. - Product Pipeline Review - 2014
Table of Contents
NovaBay Pharmaceuticals, Inc. Snapshot 4
NovaBay Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
NovaBay Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
NovaBay Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
NovaBay Pharmaceuticals, Inc. - Pipeline Products Glance 10
NovaBay Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
NovaBay Pharmaceuticals, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
NovaBay Pharmaceuticals, Inc. - Drug Profiles 13
auriclosene 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
NVC-638 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
NVC-704 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
NVC-727 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
NovaBay Pharmaceuticals, Inc. - Pipeline Analysis 18
NovaBay Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 18
NovaBay Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 19
NovaBay Pharmaceuticals, Inc. - Recent Pipeline Updates 20
NovaBay Pharmaceuticals, Inc. - Dormant Projects 24
NovaBay Pharmaceuticals, Inc. - Discontinued Pipeline Products 25
Discontinued Pipeline Product Profiles 25
auriclosene 25
NovaBay Pharmaceuticals, Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables

NovaBay Pharmaceuticals, Inc., Key Information 4
NovaBay Pharmaceuticals, Inc., Key Facts 4
NovaBay Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7
NovaBay Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8
NovaBay Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9
NovaBay Pharmaceuticals, Inc. - Phase II, 2014 10
NovaBay Pharmaceuticals, Inc. - Preclinical, 2014 11
NovaBay Pharmaceuticals, Inc. - Discovery, 2014 12
NovaBay Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 18
NovaBay Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 19
NovaBay Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 20
NovaBay Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 24
NovaBay Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 25

List of Figures

NovaBay Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 6
NovaBay Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8
NovaBay Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9
NovaBay Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 18
NovaBay Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.